Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Feature|Videos|May 2, 2024
Dr. Shore on what he's most looking forward to at AUA 2024
Author(s)Urology Times staff
Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association Annual Meeting.
Advertisement
In this video, Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association (AUA) Annual Meeting, taking place May 3-6 in San Antonio, Texas. Shore is the US chief medical officer of urology/surgical oncology at GenesisCare USA, as well as the director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina.
Advertisement
Related to this article
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.
Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
2
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
3
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
4
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
5